RespireRx Pharmaceuticals Inc (RSPI)

[NeutrinoKid]

Someone was asking about some expertise into understanding the science behind RespireRx’s pipeline. In particular, what are the concrete constraints, and challenges involved with developing safe drugs that act on the AMPA receptor. I commented a bit on this before, Ampakines push a very powerful button in the brain, and issues of toxicity have to be resolved effectively through a solid understanding of pharmacology.

Here’s a new study released as preprint on BioRXiv, you can’t get more up-to-date than that. Basically, how toxicity can arise in looked at in detail, and how to prevent it is getting better understood.

https://www.biorxiv.org/content/10.1101/2024.01.28.577446v1.abstract

“The same linkage was not observed using high concentrations of the low impact AMPAkines, CX516 (Ampalex) and CX717. We also demonstrate that CX614 produces neuronal hyper-excitability at therapeutic doses while the newer generation low impact AMPAkine CX1739 is safe at exceedingly high doses.”